ERIC FRORENZA-HUBBARD: Open Payments
NPI 1669012357 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,279 in 54 payments from 15 companies in 2025. Trend: 2023 $412 · 2024 $967 · 2025 $1,279
Food & beverage: $1,279
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 20 | $438 |
| Novartis Pharmaceuticals Corporation | 8 | $175 |
| Biosense Webster, Inc. | 3 | $158 |
| PFIZER INC. | 5 | $99 |
| Novo Nordisk Inc | 3 | $72 |
| Amgen Inc. | 3 | $67 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $48 |
| Esperion Therapeutics, Inc. | 2 | $44 |
| CVRx, Inc. | 2 | $37 |
| Actelion Pharmaceuticals US, Inc. | 1 | $29 |
Products named: Kerendia, LEQVIO, CARTO 3, Wegovy, REPATHA, VYNDAQEL, JARDIANCE, NEXLETOL.
Industry payments across NV — which companies pay providers there.
